tetano
Editor, Senior Moderator
Clin Transl Immunology
. 2020 Dec 23;9(12):e1217.
doi: 10.1002/cti2.1217. eCollection 2020.
Severe SARS-CoV-2 patients develop a higher specific T-cell response
Julie Demaret[SUP] 1 2 [/SUP], Guillaume Lef?vre[SUP] 1 2 [/SUP], Fanny Vuotto[SUP] 3 [/SUP], Jacques Trauet[SUP] 1 2 [/SUP], Alain Duhamel[SUP] 4 [/SUP], Julien Labreuche[SUP] 4 [/SUP], Pauline Varlet[SUP] 1 2 [/SUP], Arnaud Dendooven[SUP] 1 2 [/SUP], Sarah Stabler[SUP] 3 5 [/SUP], Benoit Gachet[SUP] 3 [/SUP], Jules Bauer[SUP] 3 [/SUP], Brigitte Prevost[SUP] 6 [/SUP], Laurence Bocket[SUP] 6 [/SUP], Enagnon Kazali Alidjinou[SUP] 6 [/SUP], Marc Lambert[SUP] 7 8 [/SUP], C?cile Yelnik[SUP] 7 8 [/SUP], Bertrand Meresse[SUP] 2 [/SUP], Laurent Dubuquoy[SUP] 2 [/SUP], David Launay[SUP] 2 7 [/SUP], Sylvain Dubucquoi[SUP] 1 2 [/SUP], David Montaigne[SUP] 9 [/SUP], Eloise Woitrain[SUP] 9 [/SUP], Fran?ois Maggiotto[SUP] 2 [/SUP], Mohamed Bou Saleh[SUP] 2 [/SUP], Isabelle Top[SUP] 1 [/SUP], Vincent Elsermans[SUP] 1 [/SUP], Emmanuelle Jeanpierre[SUP] 10 11 [/SUP], Annabelle Dupont[SUP] 10 11 [/SUP], Sophie Susen[SUP] 10 11 [/SUP], Thierry Brousseau[SUP] 12 [/SUP], Julien Poissy[SUP] 13 [/SUP], Karine Faure[SUP] 3 5 [/SUP], Myriam Labalette[SUP] 1 2 [/SUP], Lille Covid Research Network (LICORNE)
Affiliations
Abstract
Objectives: Assessment of the adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for studying long-term immunity and vaccine strategies. We quantified IFNγ-secreting T cells reactive against the main viral SARS-CoV-2 antigens using a standardised enzyme-linked immunospot assay (ELISpot).
Methods: Overlapping peptide pools built from the sequences of M, N and S viral proteins and a mix (MNS) were used as antigens. Using IFNγ T-CoV-Spot assay, we assessed T-cell and antibody responses in mild, moderate and severe SARS-CoV-2 patients and in control samples collected before the outbreak.
Results: Specific T cells were assessed in 60 consecutive patients (mild, n = 26; moderate, n = 10; and severe patients, n = 24) during their follow-up (median time from symptom onset [interquartile range]: 36 days [28;53]). T cells against M, N and S peptide pools were detected in n = 60 (100%), n = 56 (93.3%), n = 55 patients (91.7%), respectively. Using the MNS mix, IFNγ T-CoV-Spot assay showed a specificity of 96.7% (95% CI, 88.5-99.6%) and a specificity of 90.3% (75.2-98.0%). The frequency of reactive T cells observed with M, S and MNS mix pools correlated with severity and with levels of anti-S1 and anti-RBD serum antibodies.
Conclusion: IFNγ T-CoV-Spot assay is a reliable method to explore specific T cells in large cohorts of patients. This test may become a useful tool to assess the long-lived memory T-cell response after vaccination. Our study demonstrates that SARS-CoV-2 patients developing a severe disease achieve a higher adaptive immune response.
Keywords: ELISpot; SARS‐CoV‐2; T cells.
. 2020 Dec 23;9(12):e1217.
doi: 10.1002/cti2.1217. eCollection 2020.
Severe SARS-CoV-2 patients develop a higher specific T-cell response
Julie Demaret[SUP] 1 2 [/SUP], Guillaume Lef?vre[SUP] 1 2 [/SUP], Fanny Vuotto[SUP] 3 [/SUP], Jacques Trauet[SUP] 1 2 [/SUP], Alain Duhamel[SUP] 4 [/SUP], Julien Labreuche[SUP] 4 [/SUP], Pauline Varlet[SUP] 1 2 [/SUP], Arnaud Dendooven[SUP] 1 2 [/SUP], Sarah Stabler[SUP] 3 5 [/SUP], Benoit Gachet[SUP] 3 [/SUP], Jules Bauer[SUP] 3 [/SUP], Brigitte Prevost[SUP] 6 [/SUP], Laurence Bocket[SUP] 6 [/SUP], Enagnon Kazali Alidjinou[SUP] 6 [/SUP], Marc Lambert[SUP] 7 8 [/SUP], C?cile Yelnik[SUP] 7 8 [/SUP], Bertrand Meresse[SUP] 2 [/SUP], Laurent Dubuquoy[SUP] 2 [/SUP], David Launay[SUP] 2 7 [/SUP], Sylvain Dubucquoi[SUP] 1 2 [/SUP], David Montaigne[SUP] 9 [/SUP], Eloise Woitrain[SUP] 9 [/SUP], Fran?ois Maggiotto[SUP] 2 [/SUP], Mohamed Bou Saleh[SUP] 2 [/SUP], Isabelle Top[SUP] 1 [/SUP], Vincent Elsermans[SUP] 1 [/SUP], Emmanuelle Jeanpierre[SUP] 10 11 [/SUP], Annabelle Dupont[SUP] 10 11 [/SUP], Sophie Susen[SUP] 10 11 [/SUP], Thierry Brousseau[SUP] 12 [/SUP], Julien Poissy[SUP] 13 [/SUP], Karine Faure[SUP] 3 5 [/SUP], Myriam Labalette[SUP] 1 2 [/SUP], Lille Covid Research Network (LICORNE)
Affiliations
- PMID: 33376594
- PMCID: PMC7757425
- DOI: 10.1002/cti2.1217
Abstract
Objectives: Assessment of the adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for studying long-term immunity and vaccine strategies. We quantified IFNγ-secreting T cells reactive against the main viral SARS-CoV-2 antigens using a standardised enzyme-linked immunospot assay (ELISpot).
Methods: Overlapping peptide pools built from the sequences of M, N and S viral proteins and a mix (MNS) were used as antigens. Using IFNγ T-CoV-Spot assay, we assessed T-cell and antibody responses in mild, moderate and severe SARS-CoV-2 patients and in control samples collected before the outbreak.
Results: Specific T cells were assessed in 60 consecutive patients (mild, n = 26; moderate, n = 10; and severe patients, n = 24) during their follow-up (median time from symptom onset [interquartile range]: 36 days [28;53]). T cells against M, N and S peptide pools were detected in n = 60 (100%), n = 56 (93.3%), n = 55 patients (91.7%), respectively. Using the MNS mix, IFNγ T-CoV-Spot assay showed a specificity of 96.7% (95% CI, 88.5-99.6%) and a specificity of 90.3% (75.2-98.0%). The frequency of reactive T cells observed with M, S and MNS mix pools correlated with severity and with levels of anti-S1 and anti-RBD serum antibodies.
Conclusion: IFNγ T-CoV-Spot assay is a reliable method to explore specific T cells in large cohorts of patients. This test may become a useful tool to assess the long-lived memory T-cell response after vaccination. Our study demonstrates that SARS-CoV-2 patients developing a severe disease achieve a higher adaptive immune response.
Keywords: ELISpot; SARS‐CoV‐2; T cells.